1. Search Result
Search Result
Results for "

anthracis

" in MedChemExpress (MCE) Product Catalog:

15

Inhibitors & Agonists

2

Peptides

1

Inhibitory Antibodies

2

Natural
Products

1

Recombinant Proteins

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-76260
    Faropenem sodium
    1 Publications Verification

    Bacterial Antibiotic Infection
    Faropenem sodium is an orally bioavailable penem antibiotic. Faropenem sodium regulates inorganic phosphate transporter Npt1. Faropenem sodium inhibits M. tuberculosis (MIC of 1.3 μg/mL) and B. anthracis .
    Faropenem sodium
  • HY-17586
    Dalbavancin hydrochloride
    Maximum Cited Publications
    6 Publications Verification

    MDL-63397 hydrochloride; BI-397 hydrochloride

    Bacterial Antibiotic Infection
    Dalbavancin hydrochloride (MDL-63397 hydrochloride) is a semisynthetic lipoglycopeptide antibiotic with potent bactericidal activity against Gram-positive bacteria. Dalbavancin hydrochloride inhibits Staphylococcus aureus and Bacillus anthracis with MIC90s of 0.06 μg/mL and 0.25 μg/mL, respectively .
    Dalbavancin hydrochloride
  • HY-P9957

    ABthrax

    Bacterial Infection
    Raxibacumab (ABthrax) is a human IgG1 monoclonal antibody against Bacillus anthracis protective antigen (PA). Raxibacumab blocks the toxin’s deleterious effects by preventing binding of the protective antigen component of the anthrax toxin to its receptors in host cells, thereby blocking the toxin’s deleterious effects. Raxibacumab can be used for anti-anthrax research .
    Raxibacumab
  • HY-N2567

    Bacterial Infection Cancer
    (±)-Decursinol is a potent FtsZ inhibitor. (±)-Decursinol inhibits B. anthracis FtsZ polymerization with an IC50 of 102 μM .
    (±)-Decursinol
  • HY-164123

    Bacterial Infection
    Antibiofilm agent-9 (Compound 4) is a pyrrolomycin derivative with antibacterial activity. Antibiofilm agent-9 inhibits Bacillus anthracis with MIC of 0.031 μg/mL. Antibiofilm agent-9 exhibits antibiofilm activity with 84% biofilm inhibition (24 h, 8.0 μg/mL). Antibiofilm agent-9 exhibits a good pharmacokinetic characters in mouse model .
    Antibiofilm agent-9
  • HY-17586A

    MDL-63397; BI-397

    Bacterial Antibiotic Infection
    Dalbavancin (MDL-63397) is a semisynthetic lipoglycopeptide antibiotic with potent bactericidal activity against Gram-positive bacteria. Dalbavancin inhibits Staphylococcus aureus and Bacillus anthracis with MIC90s of 0.06 μg/mL and 0.25 μg/mL, respectively .
    Dalbavancin
  • HY-P5548

    Bacterial Infection Cancer
    CaLL is an antimicrobial peptide. CaLL has antibacterial activity against B. anthracis, B. anthracis (vegetative), and B. cepacia (MIC: 7.8, 31.3, 31.3 μg/mL) .
    CaLL
  • HY-P5691

    Bacterial Infection Cancer
    P1 is a broad-spectrum antimicrobial peptide. P1 shows antibacterial activity against Gram-positive and Gram-negative bacteria,such as B. anthracis spores and Carbapenem-resistant A. baumannii and K. pneumoniae .
    P1
  • HY-17586AS

    MDL-63397-d6; BI-397-d6

    Bacterial Antibiotic Infection
    Dalbavancin-d6 is the deuterium labeled Dalbavancin . Dalbavancin (MDL-63397) is a semisynthetic lipoglycopeptide antibiotic with potent bactericidal activity against Gram-positive bacteria. Dalbavancin inhibits Staphylococcus aureus and Bacillus anthracis with MIC90s of 0.06 μg/mL and 0.25 μg/mL, respectively .
    Dalbavancin-d6
  • HY-117831

    Bacterial Antibiotic Endogenous Metabolite Infection
    NSC-79887 is a nucleoside hydrolase (NH) inhibitor with activity against Bacillus anthracis. NSC-79887 is considered a good candidate inhibitor of nucleoside hydrolases for biological testing and further development. The pharmacokinetic (ADMET) prediction of NSC-79887 showed that all physicochemical parameters were within the acceptable range for human use .
    NSC-79887
  • HY-A0035

    Antibiotic Bacterial Infection
    Faropenem is a potent and orally active beta-lactam antibiotic. Faropenem demonstrates broad-spectrum in vitro antimicrobial activity against many gram-positive and -negative aerobes and anaerobes. Faropenem is resistant to hydrolysis by nearly all beta-lactamases, including extended-spectrum beta-lactamases and AmpC beta-lactamases. Faropenem is developed as an oral proagent, faropenem medoxomil, for the research of respiratory tract infections .
    Faropenem
  • HY-B1831

    LY 333328; Orbactiv

    Antibiotic Bacterial Infection Inflammation/Immunology
    Oritavancin (LY 333328), a semisynthetic derivative of Vancomycin (HY-B0671), is an orally active glycopeptide antibiotic with bactericidal activity against gram-positive organisms. Oritavancin shows antibacterial effect against B. anthracis, such as Ames strain with a MIC value of 0.015 g/mL. Oritavancin inhibits cell wall synthesis and disrupts the membrane potential. Oritavancin inhibits ArlS kinase activity thereby interfering the signal transduction. Oritavancin enters cells by adsorptive endocytosis, which drives it to lysosomes, where it exerts antibiotic activity .
    Oritavancin
  • HY-B1831A
    Oritavancin diphosphate
    1 Publications Verification

    LY333328 diphosphate

    Bacterial Antibiotic Infection Inflammation/Immunology
    Oritavancin diphosphate (LY333328 diphosphate), a semisynthetic derivative of Vancomycin (HY-B0671), is an orally active glycopeptide antibiotic with bactericidal activity against gram-positive organisms. Oritavancin diphosphate shows antibacterial effect against B. anthracis, such as Ames strain with a MIC value of 0.015 g/mL. Oritavancin diphosphate inhibits cell wall synthesis and disrupts the membrane potential. Oritavancin diphosphate inhibits ArlS kinase activity thereby interfering the signal transduction. Oritavancin diphosphate enters cells by adsorptive endocytosis, which drives it to lysosomes, where it exerts antibiotic activity .
    Oritavancin diphosphate
  • HY-136943

    Antibiotic Parasite Bacterial Infection
    K-41 is an orally active antibiotic. K-41 can be obtained from Streptomyces hygroscopicus. K-41 has antibacterial and antiplasmodial activity .
    K-41
  • HY-B1831AR

    Bacterial Antibiotic Infection Inflammation/Immunology
    Oritavancin (diphosphate) (Standard) is the analytical standard of Oritavancin (diphosphate). Oritavancin diphosphate (Standard), a semisynthetic derivative of Vancomycin (HY-B0671), is an orally active glycopeptide antibiotic with bactericidal activity against gram-positive organisms. Oritavancin diphosphate (Standard) shows antibacterial effect against B. anthracis, such as Ames strain with a MIC value of 0.015 g/mL. Oritavancin diphosphate (Standard) inhibits cell wall synthesis and disrupts the membrane potential. Oritavancin diphosphate (Standard) inhibits ArlS kinase activity thereby interfering the signal transduction. Oritavancin diphosphate (Standard) enters cells by adsorptive endocytosis, which drives it to lysosomes, where it exerts antibiotic activity .
    Oritavancin (diphosphate) (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: